SBRT + IMMUNOTHERAPY:
THE ABSCOPAL EFFECT EXPLAINED
SBRT can convert the irradiated tumour into an in situ vaccine — triggering systemic immune responses that attack distant metastases when combined with checkpoint inhibitors.
analyticsAt a Glance
- check_circleSBRT primes the immune system against tumour antigens
- check_circlePACIFIC trial: durvalumab after CRT doubled 5-year OS in Stage III NSCLC
- check_circleMultiple phase II trials show response rates of 30–50% with SBRT + PD-1 inhibitors
- check_circleCombination available at specialist centres in India and China
What Is the Abscopal Effect?
The abscopal effect (from the Latin ab — "away from", scopus — "target") describes tumour regression at non-irradiated distant sites following localised radiation therapy — a phenomenon driven by systemic immune activation.
“SBRT does not just kill the tumour in its crosshairs — it can teach the immune system to recognise and attack the same cancer everywhere in the body.”
Radiation as Immunogenic Cell Death
SBRT causes immunogenic tumour cell death — releasing damage-associated molecular patterns (DAMPs), tumour neoantigens, and cytokines that activate dendritic cells and prime cytotoxic T-cells against the tumour.
In Situ Vaccination
The irradiated tumour acts as an endogenous vaccine depot — releasing tumour-specific antigens directly into the immune microenvironment and priming a systemic anti-tumour response without requiring external antigen preparation.
Why Checkpoint Inhibitors Amplify SBRT's Immune Effect
SBRT alone produces the abscopal effect in a minority of patients. Checkpoint inhibitors (anti-PD-1, anti-PD-L1, anti-CTLA-4) remove immunosuppressive brakes, amplifying the T-cell response generated by radiation.
PD-1/PD-L1 Inhibitors
Pembrolizumab, nivolumab, and durvalumab block the PD-1/PD-L1 axis — preventing tumour cells from switching off the cytotoxic T-cells that SBRT activates. This combination is the most extensively studied in clinical trials.
Anti-CTLA-4 Agents
Ipilimumab (anti-CTLA-4) acts at a different checkpoint — enhancing early T-cell priming in lymph nodes. Preclinical data show synergy with SBRT, with several clinical trials ongoing in melanoma, NSCLC, and colorectal cancer.
Clinical Evidence for SBRT + Immunotherapy Combinations
Multiple phase II trials and one landmark phase III trial have established clinical proof of concept for combining radiation with immune checkpoint blockade.
PACIFIC Trial — Durvalumab After CRT, Stage III NSCLC
- Durvalumab 5-yr OS42.9%
- Placebo 5-yr OS33.4%
- Durvalumab Median PFS16.9 mo
- Placebo Median PFS5.6 mo
SBRT + Pembrolizumab — Phase II Series
- ORR at non-irradiated sites (SBRT + pembro)~31–44%
- Disease control rate (SBRT + pembro)~65–72%
Key Trials: SBRT + Immunotherapy
A growing body of randomised and single-arm trial data supports SBRT combined with immune checkpoint blockade across tumour types.
| Trial | Combination | Tumour Type | Key Finding |
|---|---|---|---|
| PACIFIC (Phase III) | Durvalumab after concurrent CRT | Stage III unresectable NSCLC | 5-yr OS 42.9% vs 33.4%; new standard of care |
| KEYNOTE-001 subset | Pembrolizumab (prior RT vs no prior RT) | Advanced NSCLC | ORR 33% in prior RT vs 19% no prior RT — suggested synergy |
| STIMULATE (Phase II) | SBRT + nivolumab + ipilimumab | Oligometastatic NSCLC | PFS benefit; abscopal responses observed in ~30% of patients |
| COSINR (Phase II) | SBRT + nivolumab | Oligometastatic NSCLC | Improved disease control; responses at non-irradiated sites confirmed |
| PEMBRO-RT (Phase II) | SBRT + pembrolizumab | Stage IV NSCLC | ORR 36% vs 18% (pembrolizumab alone); abscopal responses in ~20% |
| Multiple Phase I/II | SBRT + ipilimumab | Melanoma, NSCLC | Abscopal responses confirmed; anti-CTLA-4 timing relative to RT critical |
How to Optimise the SBRT–Immunotherapy Combination
The sequencing, dose, and site selection for SBRT within an immunotherapy regimen significantly affects the likelihood of triggering a systemic abscopal response.
Timing of Immunotherapy
Most clinical data support starting checkpoint inhibitors during or shortly after SBRT (within 1–2 weeks) to capitalise on peak T-cell priming. The PACIFIC protocol initiated durvalumab within 1–42 days of completing CRT.
SBRT Dose and Fractionation
Moderate hypofractionation (3 × 8–10 Gy) appears to generate more immunogenic cell death than single high-dose SBRT. Single fractions of 24 Gy may actually suppress T-cell influx through induction of immunosuppressive TREX1 pathways.
Site Selection for SBRT
Irradiating high-burden, immunogenic lesions (liver, lung primary) may be more effective for abscopal priming than treating bone-only metastases. Preliminary evidence suggests lesions with higher mutational burden generate stronger immune responses.
Biomarkers of Response
PD-L1 TPS ≥1%, high TMB, and evidence of pre-existing CD8+ T-cell infiltration in the tumour microenvironment are associated with higher rates of abscopal responses in published series.
Benefits and Risks of SBRT + Immunotherapy Combination
The combination amplifies both anti-tumour efficacy and the risk of immune-related adverse events — patient selection and experienced multidisciplinary management are essential.
Potential Benefits
- Systemic disease control beyond irradiated sitesAbscopal responses eliminate distant metastases not directly targeted by SBRT
- Established survival benefit (PACIFIC)Durvalumab after CRT is now the standard of care in Stage III NSCLC
- Synergistic anti-tumour immune activationSBRT primes tumour-specific T-cells; checkpoint inhibitors prevent their suppression
- Durable responses possibleA subset of patients achieve long-term disease control exceeding systemic therapy alone
Risks and Considerations
- Increased immune-related adverse events (irAEs)Combination carries higher rates of pneumonitis, colitis, hepatitis vs either modality alone
- Radiation pneumonitis risk amplifiedSBRT to lung + checkpoint inhibitors significantly elevates pneumonitis risk — requires dose monitoring
- Not all patients respondAbscopal responses observed in 20–40% — immunologically "cold" tumours have limited benefit
- Optimal sequencing not standardisedOutside PACIFIC, no Phase III data define optimal SBRT dose/fractionation for immune priming
Related SBRT Resources
Explore more in-depth guides covering SBRT across cancer types and access pathways.
Frequently Asked Questions
SBRT, Immunotherapy, and the Abscopal Effect
How common is the abscopal effect with SBRT alone?
With SBRT alone, clinically documented abscopal responses are rare — estimated at 1–5% in retrospective series. The effect is significantly more frequent and reproducible when SBRT is combined with checkpoint inhibitors, with phase II data reporting systemic response rates of 20–40% depending on histology, PD-L1 expression, and SBRT dosing strategy.
Which checkpoint inhibitors are most commonly combined with SBRT?
PD-1/PD-L1 inhibitors (pembrolizumab, nivolumab, durvalumab, atezolizumab) are most commonly studied, with the largest dataset in NSCLC. Anti-CTLA-4 agents (ipilimumab, tremelimumab) have been studied in melanoma and NSCLC phase I/II trials. Combinations of anti-PD-1 and anti-CTLA-4 with SBRT are being explored in several ongoing trials for multiple solid tumours.
Is the SBRT + immunotherapy combination standard of care outside Stage III NSCLC?
Outside the PACIFIC trial indication (Stage III unresectable NSCLC, durvalumab after CRT), the combination remains investigational or protocol-based for most tumour types. However, it is increasingly used as a rational combination strategy at experienced centres in patients with oligometastatic disease, particularly when standard systemic options are exhausted or when immune priming is desired before starting checkpoint inhibitor therapy.
What monitoring is required when combining SBRT with immunotherapy?
Close monitoring for immune-related adverse events (irAEs) is essential — particularly pneumonitis (especially with lung SBRT), colitis, hepatitis, and endocrinopathies. CT restaging at 6–8 weeks post-treatment is standard to assess response, including pseudo-progression patterns. Patients should be managed by a multidisciplinary team with expertise in both radiation oncology and immunotherapy toxicity.
Can SBRT + immunotherapy combination be accessed in India or China?
Yes. PD-1/PD-L1 inhibitors are widely available in both India and China — including locally approved biosimilars and domestically manufactured agents in China at significantly lower cost. Combined with SBRT (available at major academic centres in both countries), this combination is accessible at a fraction of Western costs. CancerFax can help evaluate eligibility for this combination and coordinate access to experienced oncology teams.
How CancerFax Helps
CancerFax is a specialist cancer access and patient-navigation platform. We help patients and families understand their options, organise medical records, coordinate hospital communication, and support cross-border treatment planning where appropriate.
We help collect and organise reports, scans, pathology, biomarker results, and treatment history for structured case review.
We communicate with hospitals or trial teams to assess whether a case may be suitable for further screening.
We support appointment coordination, document submission, translation, and direct communication with international departments.
For international patients, we help with practical coordination — travel planning, hospital admission guidance, and local support.
If this option is not suitable, we help explore other relevant treatments, clinical trials, or advanced care pathways.
From inquiry through to follow-up, our coordinators provide a single point of contact for the family.
CancerFax does not guarantee treatment access, eligibility, or clinical outcome. Our role is to help patients access accurate information, structured review, and appropriate specialist pathways.
Could SBRT + Immunotherapy Be Right for Your Case?
Upload your imaging, pathology, and treatment history. Our team will assess whether an SBRT–immunotherapy combination is clinically appropriate and connect you with specialist centres in India or China.
This content is for informational purposes only and does not constitute medical advice. Always consult a qualified oncologist before making treatment decisions.